United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc.

Nepsis Inc. lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 7.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,416 shares of the biotechnology company’s stock after selling 3,356 shares during the period. United Therapeutics accounts for 5.9% of Nepsis Inc.’s investment portfolio, making the stock its biggest position. Nepsis Inc. owned about 0.10% of United Therapeutics worth $18,620,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in UTHR. CWM LLC increased its position in United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after purchasing an additional 3,487 shares during the last quarter. AXQ Capital LP grew its stake in shares of United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares during the period. Osaic Holdings Inc. increased its holdings in shares of United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after buying an additional 33,662 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of United Therapeutics in the 3rd quarter worth $8,351,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of United Therapeutics by 77.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after buying an additional 2,655 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $485.43, for a total transaction of $4,029,069.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at $17,854,600.83. This trade represents a 18.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jan Malcolm sold 50 shares of United Therapeutics stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $512.12, for a total value of $25,606.00. Following the sale, the director owned 420 shares in the company, valued at $215,090.40. This represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 608,514 shares of company stock valued at $284,376,421. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Down 1.5%

UTHR opened at $483.23 on Friday. The firm’s 50 day moving average is $483.94 and its 200-day moving average is $401.49. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The firm has a market capitalization of $20.81 billion, a P/E ratio of 18.31, a P/E/G ratio of 2.55 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the firm earned $6.39 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on UTHR. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. UBS Group increased their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.